Acceptability of WAKA - a new online support tool for people living with schizophrenia on paliperidone injectio

Not Applicable

• Conditions: Schizophrenia; Mental Health - Schizophrenia

• Registration Number: ACTRN12618002059246
• Lead Sponsor: Dr Lyndy Matthews

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-12-21
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

People living with schizophrenia, who have been prescribed paliperidone long-acting therapy, will be invited to participate.

To be eligible for inclusion in the study service users must:

•be aged 18-65 years,
•have a diagnosis of schizophrenia,
•currently reside in one of the locations served by the recruitment sites
•be on a paliperidone long-acting therapy
•have internet access and a device that can access the internet (e.g. a smartphone)
•have capacity to provide informed consent
•be able to read and understand English at a sufficient level to provide informed consent and participate in the study.

Enrolment onto the trial is open to service users who meet the above inclusion criteria and are under a Compulsory Treatment Order (CTO).

In order to manage any ethical concerns around this issue, DHB enrollers will make it explicitly clear to potential participants that enrolling onto the trial is entirely voluntary. Enrollers will assess the initial response of individuals under CTO and provide information accordingly for those who are interested in enrolling. DHB staff will explain the aim of the study and provide any safeguards to address any feelings of coercion by the service user.

Exclusion Criteria

Service Users will be excluded if they:
•do not have daily access to the internet
•are unable to use a mobile phone or computer due to physical disabilities affecting eyesight or dexterity or do not have cognitive ability to navigate digital programmes

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Acceptability of the WAKA tool for individuals living with schizophrenia, who are treated with long-acting paliperidone injection<br><br>This will be assessed in 3 ways:<br>- Self-report questionnaire via an end of study survey. This will ask participants to rate how much they agree/ disagree with statements about how easy the WAKA tool was to use and how useful they found it for managing their health and treatment<br>- Automatic data generated from the WAKA tool. This will be information on number of log-ins, time spent on different functions of the app, % people using app after 6 months<br>- Semi-structured interview via telephone to feedback on experience of using the app[6-months- post enrolment]

Secondary Outcome Measures

Name	Time	Method
Self-reported treatment adherence to paliperidone injection<br><br>Assessed by a 1-item question Are you still having paliperidone injection Yes/No<br>If no, then participant can tick reasons for this (side effects, doctor change medication, no longer needed, don't like injections, didn't have any benefit, other)<br>[6-months-post enrolment];Social connectedness and integration<br>This is a composite measure and will be assessed by the Health Education Impact questionnaire (HeiQ) - using the Social integration and support (5 items) and Skill and Technique Acquisition (4 items) domains.<br>Participants will rate these statements from 1-5<br>[6-months post-enrolment]